文献速递血液净化与透析水电解质与酸碱

腹膜透析患者低钾血症与临床结局:PDOPPS国际研究结果

Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis-International Results from PDOPPS.
PubMed 文献 · Kidney Int Rep · 2020-11-22

基于PDOPPS 2014-2017年7国7421例腹膜透析患者,评估基线血钾与后续腹膜炎和死亡率的关系。持续低钾血症与后续腹膜炎率升高80%(K<3.5 mEq/l)及死亡率升高40%(K<4.0 mEq/l)相关,即使经过广泛病例组合调整。

要点

  • 持续低钾血症与腹膜透析患者腹膜炎和死亡率升高独立相关
  • 低钾血症在泰国和美国黑人患者中更常见
  • 蛋白能量消耗、低尿量、高透析剂量、利尿剂使用等与低钾相关

核心结论

  • 持续低钾血症与腹膜透析患者更高的死亡率和腹膜炎率相关,即使经过广泛的病例组合和潜在混杂因素调整后仍存在。

研究设计与样本

  • 国际多中心前瞻性队列研究,纳入7个国家7421例腹膜透析患者,基线血钾来自PDOPPS 2014-2017年数据。

主要发现

  • 持续低钾血症(4个月内均低钾 vs 0个月)与后续腹膜炎率升高80%(K<3.5 mEq/l)相关。
  • 持续低钾血症与死亡率升高40%(K<4.0 mEq/l)相关。
  • 4个月平均血钾<3.5 mEq/l vs 4.0-4.4 mEq/l的调整后腹膜炎率更高,风险比1.15(95%CI 0.96-1.37),主要归因于革兰阳性/培养阴性感染。
  • 低钾血症在泰国和美国黑人患者中更普遍。
  • 与血钾<4 mEq/l相关的特征/治疗包括蛋白能量消耗指标、较低尿量、较低血压、较高透析剂量、较多利尿剂使用及未处方肾素-血管紧张素系统抑制剂。

临床怎么用

  • 应监测腹膜透析患者血钾,识别持续低钾血症高风险者。
  • 对存在蛋白能量消耗、低尿量、高透析剂量、利尿剂使用等可干预因素者,考虑优化管理以纠正低钾血症。

局限性

  • 需要进一步研究阐明持续低钾血症导致不良结局的机制及可干预风险因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Hypokalemia, including normal range values <4 mEq/l, has been associated with increased peritonitis and mortality in patients with peritoneal dialysis. This study sought to describe international variation in hypokalemia, potential modifiable hypokalemia risk factors, and the covariate-adjusted relationship of hypokalemia with peritonitis and mortality. METHODS: Baseline serum potassium was determined in 7421 patients from 7 countries in the Peritoneal Dialysis Outcomes and Practice Patterns Study (2014-2017). Association of baseline patient and treatment factors with subsequent serum potassium <4 mEq/l was evaluated by logistic regression, whereas baseline serum potassium levels (4-month average and fraction of 4 months having hypokalemia) on clinical outcomes was assessed by Cox regression. RESULTS: Hypokalemia was more prevalent in Thailand and among black patients in the United States. Characteristics/treatments associated with potassium <4 mEq/l included protein-energy wasting indicators, lower urine volume, lower blood pressure, higher dialysis dose, greater diuretic use, and not being prescribed a renin-angiotensin system inhibitor. Persistent hypokalemia (all 4 months vs. 0 months over the 4-month exposure period) was associated with 80% higher subsequent peritonitis rates (at K <3.5 mEq/l) and 40% higher mortality (at K <4.0 mEq/l) after extensive case mix/potential confounding adjustments. Furthermore, adjusted peritonitis rates were higher if having mean serum K over 4 months <3.5 mEq/l versus 4.0-4.4 mEq/l (hazard ratio, 1.15 [95% confidence interval, 0.96-1.37]), largely because of Gram-positive/culture-negative infections. CONCLUSIONS: Persistent hypokalemia is associated with higher mortality and peritonitis even after extensive adjustment for patient factors. Further studies are needed to elucidate mechanisms of these poorer outcomes and modifiable risk factors for persistent hypokalemia.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Davies SJ, Zhao J, Morgenstern H, et al. Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis-International Results from PDOPPS. Kidney Int Rep. 2020. PMID: 33615056. doi:10.1016/j.ekir.2020.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。